Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production

Circulation

Volumn 93, Issue 11, 1996, Pages 2059-2067

  Ogawa, Tsuneo ^d   Linz, Wolfgang ^c   Stevenson, Michelle ^d   Bruneau, Benoit G ^b   De Kuroski Bold, Mercedes L ^a   Chen, Jia Hua ^d   Eid, Hoda ^a,b   Schölkens, Bernward A ^c   De Bold, Adolfo J ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SANOFI   (France)

^d NONE

Author keywords

aorta; collagen; myosin; natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 3; MESSENGER RNA; MYOSIN HEAVY CHAIN; RAMIPRIL; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SECRETION; SYNTHESIS;

EID: 0029934961     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.11.2059     Document Type: Article

References (58)

1. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230:767-770.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
3. de Bold AJ, Bruneau BG, Kuroski-de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31:7-18.
4. Kuroski-de Bold ML, de Bold AJ. Stretch-secretion coupling in atrial cardiocytes: dissociation between atrial natriuretic factor release and mechanical activity. Hypertension. 1991;18(suppl III): III-169-III-178.
5. Agnoletti G, Rodella A, Ferrari R, Harris P. Release of atrial natriuretic peptide-like immunoreactive material during stretching of the rat atrium in vitro. J Mol Cell Cardiol. 1987;19:217-220.
6. Yokota N, Bruneau BG, Kuroski-de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon: evidence for a guanylate cyclase-mediated pathway. J Clin Invest. 1994;94:1938-1946.
7. Yokota N, Bruneau BG, Fernandez BE, Kuroski-de Bold ML, Piazza LA, Eid H, de Bold AJ. Dissociation of cardiac hypertrophy, myosin heavy chain isoform expression, and natriuretic peptide production in DOCA-salt rats. Am J Hypertens. 1995;8:301-310.
8. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A. 1988;85:339-343.
9. Fukui K, Iwao H, Nakamura A, Yamamoto A, Tamaki T, Shoji T, Kimura S, Aki Y, Hasui K, Ohkubo H, Nakanishi S, Abe Y. Captopril and hydralazine suppress atrial natriuretic peptide (ANP) gene expression in the ventricles of spontaneously hypertensive rat. Biochem Biophys Res Commun. 1989;160:310-316.
10. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction: comparison with captopril. J Pharmacol Exp Ther. 1994;270:8-14.
11. Arvola P, Ruskoaho H, Wuorela H, Pekki A, Vapaatalo H, Pörsti I. Quinapril treatment and arterial smooth muscle responses in spontaneously hypertensive rats. Br J Pharmacol. 1993;108:980-990.
12. Oda T, Iijima Y, Sada T, Nishino H, Oizumi K, Koike H. Effects of chronic treatment with a novel angiotensin converting enzyme inhibitor, CS622, and a vasodilator, hydralazine, on atrial natriuretic factor (ANF) in spontaneously hypertensive rats (SHR). Biochem Biophys Res Commun. 1988;152:456-462.
13. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989;7: 267-275.
14. Matsubara H, Yamamoto J, Hirata Y, Mori Y, Oikawa S, Inada M. Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats. Circ Res. 1990;66:176-184.
15. Wollert KC, Studer R, von Bülow B, Drexler H. Survival after myocardial infarction in the rat. Circulation. 1994;90:2457-2467.
16. Qing G, Garcia R. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol. 1992;263:H833-H840.
17. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Kurihara N, Takeda T. Atrial and brain natriuretic peptides: secretion during exercise in patients with essential hypertension and modulation by acute angiotensin-converting enzyme inhibition. Clin Exp Pharmacol Physiol. 1992;19:193-200.
18. Yoshimura M, Yasue H, Tanaka H, Kikuta K, Sumida H, Kato H, Jougasaki M, Nakao K. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J. 1994;72:528-533.
19. Lang CC, Motwani JG, Rahman AR, Coutie WJ, Struthers AD. Effect of angiotensin-converting enzyme inhibition on plasma brain natriuretic peptide levels in patients with heart failure. Clin Sci. 1992;83:143-147.
20. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens [A]. 1989;11: 1325-1350.
21. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992;107:970-975.
22. Sarda IR, de Bold ML, de Bold AJ. Optimization of atrial natriuretic factor radioimmunoassay. Clin Biochem. 1989;22:11-15.
23. Flynn TG, Davies PL, Kennedy BP, de Bold ML, de Bold AJ. Alignment of rat cardionatrin sequences with the preprocardionatrin sequence from complementary DNA. Science. 1985;228: 323-325.
24. Bruneau BG, de Bold AJ. Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1. Cardiovasc Res. 1994;28: 1519-1525.
25. Mori N, Singer-Sam J, Lee CY, Riggs AD. The nucleotide sequence of a cDNA clone containing the entire coding region for mouse X-chromosome-linked phosphoglycerate kinase. Gene. 1986;45:275-280.
26. Glumoff V, Makela JK, Vuorio E. Cloning of cDNA for rat pro alpha 1(III) collagen mRNA: different expression patterns of type I and type III collagen and fibronectin genes in experimental granulation tissue. Biochim Biophys Acta. 1994;1217:41-48.
27. McNally EM, Gianola KM, Leinwand LA. Complete nucleotide sequence of full length cDNA for rat alpha cardiac myosin heavy chain. Nucl Acids Res. 1989;17:7527-7528.
28. Kraft R, Bravo-Zehnder M, Taylor DA, Leinwand LA. Complete nucleotide sequence of full length cDNA for rat beta cardiac myosin heavy chain. Nucl Acids Res. 1989;17:7529-7530.
29. Schölkens BA, Linz W, Martorana PA. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol. 1991;18(suppl 2):S26-S30.
30. Lièvre M, Guéret P, Gayet C, Roudaut R, Haugh MC, Delair S, Boissel J, for the HYCAR Study Group. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension. 1995;25:92-97.
31. Rockman HA, Wachhorst SP, Mao L, Ross JJ. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol. 1994;266: H2468-H2475.
32. Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, Saito Y, Suga S, Jougasaki M, Imura H. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats: the ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991;69:491-500.
33. Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells: an in vitro model of load-induced cardiac hypertrophy. J Biol Chem. 1992;267:10551-10560.
34. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
35. Linz W, Schölkens BA, Lindpaintner K, Ganten D. Cardiac renin-angiotensin system. Am J Hypertens. 1989;2:307-310.
36. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE, Dzau VJ. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest. 1992;90:1523-1529.
37. Baker KM, Chemin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324-H332.
38. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
39. Linz W, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.
40. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension. 1992;20:478-482.
41. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GAJ, Schunkert H. Blockade of renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250-259.
42. Becker RH, Linz W, Schölkens BA. Pharmacological interference with the cardiac renin-angiotensin system. J Cardiovasc Pharmacol. 1989;14(suppl 4):S10-S15.
43. Vasmant D, Bender N. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor. J Cardiovasc Pharmacol. 1989; 14(suppl 4):S46-S52.
44. Rhaleb NE, Yang XP, Scicli AG, Carretero OA. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension. 1994;23(pt 2):865-868.
45. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
46. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 1990;265:20555-20562.
47. McDonough PM, Brown JH, Glembotski CC. Phenylephrine and endothelin differentially stimulate cardiac PI hydrolysis and ANF expression. Am J Physiol. 1993;264:H625-H630.
48. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
49. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994;89:2198-2203.
50. Eid H, Kuroski-de Bold ML, Chen JH, de Bold AJ. Epicardial mesothelial cells synthesize and secrete endothelin. J Cardiovasc Pharmacol. 1994;24:715-720.
51. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
52. Wang D, Chen J, Shin N, Kao Y, Hsu K, Huang W, Liew C. Endothelin stimulates cardiac α- and β-myosin heavy chain gene expression. Biochem Biophys Res Commun. 1992;183:1260-1265.
53. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
54. Arai M, Yoguchi A, Iso T, Takahashi T, Imai S, Murata K, Suzuki T. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol. 1995;268:H2084-H2091.
55. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989;13:1637-1652.
56. Liau G, Yamada Y, de Crombrugghe B. Coordinate regulation of the levels of type III and type I collagen mRNA in most but not all mouse fibroblasts. J Biol Chem. 1985;260:531-536.
57. Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, Ramacci MT, Lagrasta C, Olivetti G, Carbonin P. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension. 1991;18:148-157.
58. Imamura S, Matsuoka R, Hiratsuka E, Kimura M, Nakanishi T, Nishikawa T, Furutani Y, Takao A. Adaptational changes of MHC gene expression and isozyme transition in cardiac overloading. Am J Physiol. 1991;260(pt 2):H73-H79.